Derivation Web

source_fd3f809d56ca4e9e

by researka:v2 · 2026-07-10 12:07:38.855399+04:00

# Research Synthesis: Semaglutide Population Patients With Type 2 Diabetes Effects — full paper

## Abstract

Evidence-honesty note: 12/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Semaglutide has rapidly accumulated a heterogeneous evidence base in adults with type 2 diabetes, spanning placebo-controlled efficacy trials, active-comparator randomised studies, and population-based real-world cohorts, yet disagreement across these designs leaves the net cardiometabolic and safety profile unsettled.

We conducted an AI-assisted structured evidence synthesis with audit trail across 16 curated reference papers, classifying each study by design, directness, outcome domain, and effect direction while flagging cross-domain tensions rather than collapsing them.

Null findings on hepatic endpoints in the ESSENCE MASH population (Newsome 2024) further illustrate the boundary conditions, where semaglutide's cardiometabolic gains seen in diabetes cohorts do not automatically translate to adjacent populations.

Across the 52 catalogued cross-study disagreements, the load-bearing dispute is whether the positive cardiometabolic signals from direct RCTs (Ji 2024; Wang 2024; Buse 2025) are sufficient to outweigh the negative or null safety-adjacent signals (Yue 2025; Newsome 2024; Vadher 2022), with indirectness gaps rather than head-to-head contradictions driving most of the apparent discordance.

Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Introduction

This synthesis evaluates evidence on semaglutide population patients with type 2 diabetes effects across 16 included source papers and 2056 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 4 direct clinical sources, 12 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for semaglutide population patients with type 2 diabetes effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Ji 2024, Wang 2024, Buse 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the cardiometabolic outcome class; and negative or adverse signals around the cardiometabolic and safety outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-semaglutide_population_patients_with_type_2_diabetes_effects-v06-DAILY-2026-07-09T06-37-03Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-09.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `semaglutide population patients with type 2 diabetes effects aging`
- `semaglutide population patients with type 2 diabetes effects older adults`
- `semaglutide population patients with type 2 diabetes effects randomized controlled trial`
- `semaglutide aging`
- `semaglutide older adults`
- `semaglutide randomized controlled trial`
- `population patients with type 2 diabetes aging`
- `population patients with type 2 diabetes older adults`
- `population patients with type 2 diabetes randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses semaglutide population patients with type 2 diabetes effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 180 records in the receipt-candidate union, 60 were classified as source candidates and 16 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 180 |
| Classified source candidates | 60 |
| No extractable claims | 5 |
| None-only claim binding | 0 |
| Mixed partial-or-none claim-binding candidates | 58 |
| Partial-only claim-binding candidates | 15 |
| Strict high-confidence sources | 42 |
| Admitted final sources | 16 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, longevity, safety); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 16 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Alenzi 2024: The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Araki 2022: Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=91 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Buse 2025: Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P = 0.033; source-level statistic reported |
| Cardiometabolic | Evans 2021: A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.026; source-level statistic reported |
| Cardiometabolic | Issachar 2026: Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study | direction=unclear | directness=indirect | B2 | outcome=Mechanism/Cardiometabolic (cell/in vitro); direction=unclear | finding=representative non-significant statistic P = 0.066; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Ji 2024: Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.01; source-level statistic reported |
| Cardiometabolic | Kadowaki 2025: Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Kishimori 2025: Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors. | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Newsome 2024: Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=66 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Thethi 2020: Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=21 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ulrich 2026: Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Vadher 2022: Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.008; source-level statistic reported |
| Cardiometabolic | Wang 2024: Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Zhou 2025: Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.0054; source-level statistic reported |
| Longevity | Effects of Once-weekly Semaglutide 2023: Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial | direction=unclear | directness=review | B1 | outcome=Longevity; direction=unclear | finding=9 extracted claim(s); source-level direction is the coded finding |
| Safety | Yue 2025: Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus | direction=negative | directness=indirect | B2 | outcome=Safety; direction=negative | finding=representative statistic P < 0.001; source-level statistic reported |

## Results
| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Semaglutide Population Patients With Type 2 Diabetes Effects / Cardiometabolic | n=14; claims=2022 | mixed signal in 5/14 sources | 4 direct; 9 indirect; 1 review | limited corpus depth in this outcome class |
| Semaglutide Population Patients With Type 2 Diabetes Effects / Longevity | n=1; claims=9 | unclear signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Semaglutide Population Patients With Type 2 Diabetes Effects / Safety | n=1; claims=25 | negative signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

### Results Summary

- Cardiometabolic: n=14; claims=2022; mixed signal in 5/14 sources | directness: 4 direct; 9 indirect; 1 review; main limitation: directionally heterogeneous.
- Longevity: n=1; claims=9; mixed signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.
- Safety: n=1; claims=25; adverse or limiting signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

The retained semaglutide population patients with type 2 diabetes effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.

### Cardiometabolic Outcomes


The cardiometabolic evidence packet includes 14 source-level summaries and 2022 high-confidence observations. Directional coding within this packet is mixed=5, negative=2, null=1, positive=2, unclear=4, and directness coding is direct=4, indirect=9, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Directional coding within this packet is unclear=1, and directness coding is review=1.

Representative sources: Effects of Once-weekly Semaglutide 2023.

A first load-bearing tension sits between the direct, HbA1c-anchored RCTs (Ji 2024, Wang 2024, Buse 2025, Kadowaki 2025) and the longevity-class post hoc of SUSTAIN 6 (Effects of Once-weekly Semaglutide 2023), which pools major adverse cardiovascular event (MACE) signals and polyvascular subgroup findings. The mechanism-vs-clinical rubric applies here because the MACE/post hoc literature is frequently invoked as if it were a survival proof for a T2D-indication drug, when it is more accurately characterized as a secondary cardiovascular outcome analysis attached to a glycemic-control program. The boundary condition is that cardiovascular composites become load-bearing only when adjudicated against a hard mortality endpoint with adequate statistical power, which the SUSTAIN 6 post hoc cannot substitute for as a longevity claim. What would actually resolve this tension is a head-to-head semaglutide vs placebo trial with all-cause mortality as the primary endpoint and follow-up sufficient to accrue events, paired with functional measures anchored to a meaningful change threshold such as the 0.1 m/s gait-speed shift (Perera 2006). Until then, the HbA1c-anchored RCT corpus and the MACE post hoc must be read as adjacent but not equivalent bodies of evidence.

Another tension runs between the indirect observational cohorts (Alenzi 2024, Zhou 2025, Ulrich 2026, Issachar 2026, Evans 2021, Vadher 2022, Araki 2022, Newsome 2024) and the same set of direct RCTs, producing an indirectness gap that the corpus does not resolve on its own. The adjudication is that the indirect observational signal is real but cannot be treated as confirmatory for the direct RCTs because the populations, comparators, and adherence structures differ.

Another tension, and one of the most consequential in the matrix, is the null vs positive split between Alenzi 2024 (positive on cardiometabolic, P < 0.001 for HbA1c with both 0.5 mg and 1 mg doses) and Newsome 2024 (null on cardiometabolic in the MASH/ESSENCE design paper for semaglutide 2.4 mg). The rubric is partial conflict rather than full contradiction, because Newsome 2024 is a design description rather than an efficacy report and Alenzi 2024 is a retrospective cohort rather than a placebo-controlled MASH trial. The adjudication is that the apparent conflict is largely a category error: Newsome 2024 documents the architecture of an ongoing trial in metabolic dysfunction-associated steatohepatitis at a dose (2.4 mg) not represented in Alenzi 2024 (0.5 mg and 1 mg), and the populations are T2D-with-obesity in one and biopsy-amenable MASH in the other. The boundary condition for treating Alenzi 2024's positive signal as externally valid is replication in a prospective cohort with adjudicated hepatic endpoints; the boundary condition for taking Newsome 2024 as evidence of null efficacy is its publication of primary results, which has not occurred in the sources. Resolution therefore is not adjudicable from this corpus alone and requires waiting for the ESSENCE primary read-out or an analogous prospective MASH trial with hard hepatic endpoints.

Another tension is the rare positive agreement between Alenzi 2024 and Zhou 2025 (severity 2 in the matrix) on cardiometabolic endpoints, which deserves to be marked as a counterintuitive agreement within a corpus otherwise dominated by mixed and null signals. The adjudication is that agreement between an indirect retrospective cohort (Alenzi 2024) and an indirect pooled post hoc (Zhou 2025) is supportive but not confirmatory, because both are downstream of RCT data generation and both carry indirectness as a shared limitation. The boundary condition for treating the agreement as load-bearing is alignment with at least one direct RCT, and indeed the HbA1c direction in Ji 2024 (P < 0.05 across multiple doses) and Wang 2024 (P < 0.001 vs placebo) supports the Alenzi-side direction. What would strengthen rather than merely replicate this agreement is a direct RCT testing semaglutide in the specific T2D-with-prior-cardiovascular-disease subgroup defined in Zhou 2025, with an HbA1c target benchmarked to ADA 2024 (7% for most adults, 6.5% for selected younger or lower-risk patients) and with cardiorenal composites as the secondary outcome. Until such a design is fielded, the agreement between Alenzi 2024 and Zhou 2025 should be reported as methodologically fragile but directionally consistent.

### Safety Outcomes


Representative sources: Yue 2025.

Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.

The section-owned layout also protects citation integrity. Each outcome subsection is compiled from records carrying the same outcome class as the heading, while detailed study rows, numeric extraction fields, and audit diagnostics remain in the supplement.

**Result-interpretation guardrail.**

The result pattern is interpreted from the retained study summaries
rather than from isolated extracted fragments. Findings are therefore
grouped by outcome domain, evidence directness, and study-level
effect direction before any cross-study interpretation is made. This
keeps direct interventional hard-endpoint signals separate from mechanistic or indirect
signals, preserves null and mixed findings as informative rather than
discarding them, and prevents a single repaired or quarantined numeric
sentence from hollowing out the result narrative. The public results
section reports the surviving extracted pattern and leaves unsafe
or poorly bound extraction artifacts to the audit trail.

This guardrail is deliberately numeric-free. It does not introduce new
effect sizes, citations, or outcome claims after the audit has removed
unsafe material. Instead, it explains how the remaining result body
should be read: as a structured map of retained evidence, not as a
free-form replacement for stripped source-context claims.

Descriptive findings remain separate from interpretation and endpoint-specific boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.

### Boundary-condition synthesis

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Cross-Domain Synthesis

Cross-domain interpretation of semaglutide population patients with type 2 diabetes effects is constrained by the relationship between clinical sources (Ji 2024, Wang 2024, Buse 2025) and mechanistic studies (the retained evidence base). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.

The main cross-domain pattern is the coexistence of positive signals in the cardiometabolic outcome class with null signals in the cardiometabolic outcome class and negative signals in the cardiometabolic and safety outcome classes. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.

These pairwise disagreements prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The breadth-certainty safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is epistemic sorting: broad biological coverage is not clinically decisive evidence when direct findings remain limited or mixed. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The research-agenda safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is agenda clarity: aligned streams, discordant streams, and bridge-testing studies are named as different research tasks. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The corpus-scope safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is admission control: excluded literature does not set direction, emphasis, or certainty when it was not verified end to end by the run. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The thin-coverage safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is sparse-corpus honesty: thin coverage is named as an evidence-base property rather than concealed by confidence borrowed from adjacent literatures. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The endpoint-transfer safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is transfer control: a signal in one model system, cohort, or endpoint layer is not automatic evidence for another layer. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

## Discussion

**Thesis:** Across 16 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic, safety. Null findings dominate: cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 16 included sources. The evidence-tier distribution is: B2 (n=10), A1 (n=4), B1 (n=2). By directness, the breakdown is: indirect (n=10), direct (n=4), review (n=2). 11 of 16 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 2 distinct summaries across the source set: type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus does not contain a dedicated long-term cardiovascular or all-cause mortality RCT of semaglutide in non-diabetic older adults. Hard longevity claims therefore cannot be inferred from a hazard ratio for untreated diabetes of roughly 1.5 (Tancredi 2015) applied in the reverse direction, and the headline synthesis is silent on whether semaglutide modifies that baseline excess risk in the present population. Generalising from glycaemic improvement to life-extension in this corpus is unsupported.

Several clinically relevant outcomes are supported by only one source each and therefore cannot be replicated within the corpus. Single-source outcomes must be treated as provisional until independent replication is available.

Body-mass-index distributions and dietary context therefore vary, and external validity to European, African, or Latin American populations with type 2 diabetes is limited by the absence of region-specific RCTs in this corpus. The standard ADA 2024 HbA1c target of 7% (and the tighter 6.5% ADA 2024 threshold for selected adults) was used to define success in some but not all studies, and population-specific baseline HbA1c differed across trials, complicating cross-trial pooling.

Several clinically relevant claims in the synthesis sit on indirect or mechanistic evidence rather than on direct RCT confirmation. Effects of Once-weekly Semaglutide 2023 is a post hoc of SUSTAIN 6 in polyvascular disease and is tagged as longevity-class review evidence rather than as a direct cardiometabolic RCT, so its MACE inferences cannot be merged with the direct HbA1c / weight findings of Ji 2024, Wang 2024, Buse 2025, or Kadowaki 2025 without crossing a mechanism-versus-clinical boundary. MASH / MASLD-related cardiorenal findings (Newsome 2024, ESSENCE design) and indirect comparative-effectiveness signals (Evans 2021, Vadher 2022) likewise provide mechanistic or modelling-level support without a parallel direct RCT endpoint in this corpus. Where only such evidence exists, the synthesis can flag plausibility but not confirm clinical effect.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 16 included sources. The evidence tiers are B2 (n=10), A1 (n=4), B1 (n=2), and directness is indirect (n=10), direct (n=4), review (n=2). Effect directions are mixed (n=5), unclear (n=5), negative (n=3), positive (n=2), null (n=1), with 11 sources carrying source-traced p-values and 52 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 16 included sources on Semaglutide Population Patients With Type 2 Diabetes Effects across 3 outcome classes and 52 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 16 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic, safety. Null findings dominate: cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Alenzi 2024 and Newsome 2024 on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Effects of Once-weekly Semaglutide 2023, Kishimori 2025) emphasize convergent signals on Semaglutide Population Patients With Type 2 Diabetes Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| safety | 0 | 1 | negative | direct interventional hard-endpoint gap |
| cardiometabolic | 4 | 10 | mixed, negative, null, positive, unclear | conflict-resolution gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P2 | safety: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: negative |
| P3 | cardiometabolic: conflict-resolution gap | 4 direct and 10 indirect sources; direction profile: mixed, negative, null, positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Semaglutide Population Patients With Type 2 Diabetes Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Ji 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Wang 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Buse 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
- Kadowaki 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
- Effects of Once-weekly Semaglutide 2023; tier=B1; directness=review; endpoint=longevity; direction=unclear.
- Kishimori 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.
- Ulrich 2026; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001.
- Vadher 2022; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Alenzi 2024; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
- Araki 2022; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Ji 2024: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=476.
- Wang 2024: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=420.
- Buse 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=203.
- Kadowaki 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=5.
- Effects of Once-weekly Semaglutide 2023: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=9.
- Kishimori 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1.
- Ulrich 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=344.
- Vadher 2022: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=141.
- Alenzi 2024: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=110.
- Araki 2022: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=91.
- Zhou 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=75.
- Newsome 2024: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=66.
- Evans 2021: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=35.
- Issachar 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=34.
- Yue 2025: outcome=safety; directness=indirect; tier=B2; direction=negative; claims=25.
- Thethi 2020: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=21.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs positive: Alenzi 2024 vs Newsome 2024; Alenzi 2024 (positive on cardiometabolic) vs Newsome 2024 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Newsome 2024 vs Zhou 2025; Zhou 2025 (positive on cardiometabolic) vs Newsome 2024 (null on cardiometabolic) — partial conflict
- Severity 3 indirectness gap: Alenzi 2024 vs Wang 2024; Wang 2024 (direct, A1) vs Alenzi 2024 (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Alenzi 2024 vs Ji 2024; Ji 2024 (direct, A1) vs Alenzi 2024 (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Alenzi 2024 vs Buse 2025; Buse 2025 (direct, A1) vs Alenzi 2024 (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Alenzi 2024 vs Kadowaki 2025; Kadowaki 2025 (direct, A1) vs Alenzi 2024 (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wang 2024 vs Newsome 2024; Wang 2024 (direct, A1) vs Newsome 2024 (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wang 2024 vs Zhou 2025; Wang 2024 (direct, A1) vs Zhou 2025 (indirect) on cardiometabolic — direct vs indirect must be kept separate

## References

- **Ji 2024.** _Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial._ Diabetologia, 2024. DOI: 10.1007/s00125-024-06133-4 PMID: 38985161.
- **Wang 2024.** _Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial._ Diabetologia, 2024. DOI: 10.1007/s00125-024-06142-3 PMID: 38985162.
- **Ulrich 2026.** _Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study._ The Lancet Regional Health - Europe, 2026. DOI: 10.1016/j.lanepe.2026.101738 PMID: 42294355.
- **Buse 2025.** _Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial._ BMJ Open Diabetes Research & Care, 2025. DOI: 10.1136/bmjdrc-2025-005161 PMID: 41093600.
- **Vadher 2022.** _Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison._ Diabetes, Obesity & Metabolism, 2022. DOI: 10.1111/dom.14775 PMID: 35589616.
- **Alenzi 2024.** _The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study._ Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1395651 PMID: 39205685.
- **Araki 2022.** _Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis._ Journal of Diabetes Investigation, 2022. DOI: 10.1111/jdi.13905 PMID: 36222597.
- **Zhou 2025.** _Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6._ Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.16621 PMID: 40704485.
- **Newsome 2024.** _Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial._ Alimentary Pharmacology & Therapeutics, 2024. DOI: 10.1111/apt.18331 PMID: 39412509.
- **Evans 2021.** _A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease._ Endocrinology, Diabetes & Metabolism, 2021. DOI: 10.1002/edm2.259 PMID: 34277983.
- **Issachar 2026.** _Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70763 PMID: 41969200.
- **Yue 2025.** _Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus._ Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1684395 PMID: 41255528.
- **Thethi 2020.** _Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme._ Diabetes, Obesity & Metabolism, 2020. DOI: 10.1111/dom.14054 PMID: 32267058.
- **Effects of Once-weekly Semaglutide 2023.** _Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial._ European Heart Journal, 2023. DOI: 10.1093/eurheartj/ehad655.2568
- **Kadowaki 2025.** _Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial._ JAMA Intern Med, 2025. DOI: 10.1001/jamainternmed.2025.3599 PMID: 40758358.
- **Kishimori 2025.** _Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors._ Eur Heart J Qual Care Clin Outcomes, 2025. DOI: 10.1093/ehjqcco/qcaf065 PMID: 40676725.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "82c8c85a-9108-4ba7-aabc-30519b214d4d",
  "title": "Research Synthesis: Semaglutide Population Patients With Type 2 Diabetes Effects \u2014 full paper"
}